This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.

Start Date16 Nov 2023

Sponsor / Collaborator-

NCT05152381 / SuspendedPhase 1IIT

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Osteoporosis

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Osteoporosis

Start Date08 Dec 2022

Sponsor / Collaborator-

NCT05018832 / Not yet recruitingPhase 1IIT

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Traumatic Brain Injury

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of traumatic brain injury

Start Date01 Dec 2022

Sponsor / Collaborator-

100 Clinical Results associated with AlloRx(Vitro Biopharma)

100 Translational Medicine associated with AlloRx(Vitro Biopharma)

100 Patents (Medical) associated with AlloRx(Vitro Biopharma)

Literatures (Medical) associated with AlloRx(Vitro Biopharma)

01 Dec 2020·Journal of Translational MedicineQ2 · MEDICINE

Allogeneic administration of human umbilical cord-derived mesenchymal stem/stromal cells for bronchopulmonary dysplasia: preliminary outcomes in four Vietnamese infants

Q2 · MEDICINE

ArticleOA

Author: Nguyen, Liem Thanh ; Nguyen, Kien T ; Nguyen, Anh T T ; Trinh, Nhung T H ; Hoang, Duc M ; Bui, Hue T H ; Hoang, Van T ; Trieu, Thai T H

AbstractBackgroundBronchopulmonary dysplasia (BPD) is a severe condition in premature infants that compromises lung function and necessitates oxygen support. Despite major improvements in perinatal care minimizing the devastating effects, BPD remains the most frequent complication of extreme preterm birth. Our study reports the safety of the allogeneic administration of umbilical cord-derived mesenchymal stem/stromal cells (allo-UC-MSCs) and the progression of lung development in four infants with established BPD.MethodsUC tissue was collected from a healthy donor, followed by propagation at the Stem Cell Core Facility at Vinmec Research Institute of Stem Cell and Gene Technology. UC-MSC culture was conducted under xeno- and serum-free conditions. Four patients with established BPD were enrolled in this study between May 25, 2018, and December 31, 2018. All four patients received two intravenous doses of allo-UC-MSCs (1 million cells/kg patient body weight (PBW) per dose) with an intervening interval of 7 days. Safety and patient conditions were evaluated during hospitalization and at 7 days and 1, 6 and 12 months postdischarge.ResultsNo intervention-associated severe adverse events or prespecified adverse events were observed in the four patients throughout the study period. At the time of this report, all patients had recovered from BPD and were weaned off of oxygen support. Chest X-rays and CT scans confirmed the progressive reductions in fibrosis.ConclusionsAllo-UC-MSC administration is safe in preterm infants with established BPD.Trial registration This preliminary study was approved by the Vinmec International Hospital Ethics Board (approval number: 88/2019/QĐ-VMEC; retrospectively registered March 12, 2019).

100 Deals associated with AlloRx(Vitro Biopharma)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Amyotrophic Lateral Sclerosis	Phase 3	-	Vitro Biopharma, Inc.	-
Autistic Disorder	Phase 3	-	Vitro Biopharma, Inc.	-
Diabetes Mellitus	Phase 3	-	Vitro Biopharma, Inc.	-
Inflammatory Bowel Diseases	Phase 3	-	Vitro Biopharma, Inc.	-
Osteoarthritis	Phase 3	-	Vitro Biopharma, Inc.	-
Rheumatoid Arthritis	Phase 3	-	Vitro Biopharma, Inc.	-
Pitt-Hopkins Syndrome	Discovery	-	Vitro Biopharma, Inc.	01 Dec 2021
Idiopathic Pulmonary Fibrosis	Discovery	AG	Vitro Biopharma, Inc.	23 Aug 2021
Scleroderma, Systemic	Discovery	AG	Vitro Biopharma, Inc.	23 Aug 2021
Multiple Sclerosis	Discovery	AG	Vitro Biopharma, Inc.	12 Aug 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

AlloRx(Vitro Biopharma)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation